[Treatment of ALL in children. Results and side effects with a modification of protocol memphis VII (author's transl)].
42 patients with ALL were treated according to the following protocol: induction with vincristine + prednisone (+/- L-asparaginase), CNS-prophylaxis with cranial irradiation (2400 rads) and intrathecal methotrexate, maintenance for 3 years with 6-MP 50 mg/m2/d p.o. + MTX 75-150 mg/m2/2 wk i.v. X 4, alternating in a cyclic fashion with 6-MP 50 mg/m2/d p.o. + cyclophophshamide 600 mg/m2/2 wk i.v. X 4. The observation time is 24-67 (median 49) months. The actuarial complete remission curve shows 40% continuous complete remissions at 36 months and 30% at 60 months.--The frequency and temporal distribution of typical infectious complications are presented. The incidence of varicella was comparable to that in a southgerman normal control group (5,7% per year). During treatment there were two zoster manifestations per one varicella case, the incidence of zoster being 1 case per 106 patient-months, viz 11,4% per year.
D000293:Adolescent; D001215:Asparaginase / Q000627:therapeutic use; D002644:Chickenpox / Q000150:complications; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006562:Herpes Zoster / Q000150:complications; D006801:Humans; D007223:Infant; D007278:Injections, Spinal; D007945:Leukemia, Lymphoid / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D012886:Skull; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate
Zur Therapie der ALL. Modifikation des Behandlungsplanes Memphis VII.